Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iPRIME^™ Viscodelivery System, which is designed for the delivery of viscoelastic fluid during ophthalmic surgery. This sterile, single-use device represents an advancement in minimally invasive glaucoma surgery (MIGS) technology. CEO Thomas Burns highlighted the importance of this clearance in expanding Glaukos' innovative ophthalmic solutions and maintaining their leadership in the MIGS marketplace.

Glaukos Corporation (NYSE: GKOS) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET. The event will be accessible via a live and archived webcast on Glaukos' investor relations website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent devices, launched between 2012 and 2020, and offers pharmaceuticals for corneal health enhancement.

Glaukos Corporation (NYSE: GKOS) announced the retirement of Chairman William J. Link, effective December 31, 2021, after two decades of service. Thomas W. Burns, President and CEO, will succeed him as Chairman. The board also appointed Mark J. Foley as lead independent director. The company expressed gratitude for Link's contributions and confidence in Burns' leadership for future growth and innovation in treating chronic eye diseases.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its management's participation in key investor conferences. Highlights include a pre-recorded presentation at the Piper Sandler Annual Healthcare Conference available from November 22, 2021, along with one-on-one meetings on December 1, 2021. Additionally, Glaukos will feature at the Stephens Annual Investment Conference on November 29, 2021. Interested parties can access live and archived webcasts in the Investors section of the Glaukos website.

Glaukos Corporation (NYSE: GKOS) announced its participation in the American Academy of Ophthalmology (AAO) annual meeting from November 12-15, 2021, in New Orleans, Louisiana. Their technologies will be featured in various scientific programs, highlighting significant presentations on glaucoma and corneal health. Key topics include patient outcomes from different glaucoma surgeries and long-term effectiveness of corneal treatments. Glaukos will also exhibit at booth #4015, showcasing its innovations in ophthalmic medical technology.

Glaukos Corporation (GKOS) reported a 15% increase in net sales for Q3 2021, reaching $74.7 million, up from $64.8 million in Q3 2020. Key segments included glaucoma sales of $58.5 million and corneal health sales of $16.2 million. The gross margin was approximately 79%, and operating expenses totaled $48.3 million. Net income for the quarter was $6.2 million, or $0.13 per diluted share, compared to a net loss of $15.7 million in the prior year. The company anticipates full-year net sales between $285 million to $290 million.

Glaukos Corporation (NYSE: GKOS) will announce its third quarter 2021 financial results after market close on November 4, 2021. A conference call and webcast will follow at 1:30 p.m. PDT. Investors can access the live webcast via the company's website. The company specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, including the pioneering Micro-Invasive Glaucoma Surgery (MIGS) and its iStent® devices.

Glaukos Corporation (NYSE: GKOS) announced its participation in the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting from October 8-11, 2021, in Amsterdam. The company will showcase its technologies through key presentations and educational symposiums on glaucoma and corneal health. Notable research includes the impact of the iStent inject in glaucoma surgeries, and customized corneal cross-linking for keratoconus. Glaukos aims to highlight its innovations in minimally invasive surgical options to improve patient care in ophthalmology.

Glaukos Corporation (NYSE: GKOS) has entered a licensing agreement with Attillaps Holdings, granting Glaukos an exclusive, global license to develop and commercialize Attillaps' investigational compounds targeting Demodex mites, which cause Demodex blepharitis and related ophthalmic diseases. This agreement enhances Glaukos' Corneal Health franchise and aims to address unmet medical needs in ophthalmology. Attillaps' lead compounds have shown promising preclinical results, although financial terms were not disclosed.